EXHIBIT (A)(14)
Published on December 10, 2009
Exhibit (a)(14)
EMERSON TENDER OFFER FOR AVOCENT TO EXPIRE ON
DECEMBER 10
NO FURTHER EXTENSIONS EXPECTED
ST. LOUIS, MO, December 9, 2009 -- As
previously announced, on October 15, 2009, Emerson (NYSE: EMR) commenced a
tender offer to acquire all of the outstanding shares of common stock of Avocent
Corporation (NASDAQ: AVCT) for $25.00 per share in cash, without interest, less
certain applicable taxes. The offer is currently scheduled to expire
at 5:00 p.m., EST, on Thursday, December 10, 2009. While there can be
no assurance that the tender offer conditions will be satisfied on December
10, 2009, Emerson does not expect that the offer will need to be extended
beyond its current expiration date.
About
Emerson
Emerson
(NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing
technology and engineering together to provide innovative solutions to customers
through its network power, process management, industrial automation, climate
technologies, and appliance and tools businesses. Emerson’s sales in fiscal 2009
were $20.9 billion. Emerson is ranked 94th on the Fortune 500 list of
America’s largest companies. For more information, visit www.Emerson.com.
Forward-looking
statements
This
document contains certain forward-looking statements. These forward-looking
statements may be identified by words such as “believes”, “expects”,
“anticipates”, “projects”, “intends”, “should”, “seeks”, “estimates”, “future”
or similar expressions or by discussion of, among other things, strategy, goals,
plans or intentions. Various factors may cause actual results to differ
materially in the future from those reflected in forward-looking statements
contained in this document, among others: (1) economic and currency conditions;
(2) market demand; (3) pricing; (4) competitive and technological factors; (5)
the risk that the transaction may not be consummated; (6) the risk that a
regulatory approval that may be required for the transaction is not obtained or
is obtained subject to conditions that are not anticipated; (7) the risk that
Avocent will not be integrated successfully into Emerson; and (8) the risk that
revenue opportunities, cost savings and other anticipated synergies from the
transaction may not be fully realized or may take longer to realize than
expected.
Additional
Information and Where to Find it
This
document is for informational purposes only and does not constitute an offer to
purchase or a solicitation of an offer to sell Avocent common stock. The tender
offer is being made pursuant to a tender offer statement on Schedule TO
(including the Offer to Purchase, Letter of Transmittal and other related tender
offer materials) filed by Emerson with the Securities and Exchange Commission
(SEC) on October 15, 2009. Avocent also has filed a solicitation/recommendation
statement on Schedule 14D-9 with respect to the offer. These materials, as they
may be amended from time to time, contain important information, including the
terms and conditions of the offer, that should be read carefully before any
decision is made with respect to the tender offer. Investors and security
holders may obtain a free copy of these materials by contacting the information
agent for the tender offer, Morrow & Co., LLC, at (800) 607-0088
(toll-free).
|
Contact:
|
Mark Polzin (314) 982-1758
or William Walkowiak (314)
982-8622
|